Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort - JACRE-R

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014817

Enrollment

1100

Registered

2014-08-11

Start date

2014-07-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation patients scheduled to undergo the catheter ablation procedure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation patients scheduled to undergo the catheter ablation procedure and to have been receiving rivaroxaban for at least 3 weeks at the time of admission for catheter ablation procedure

Exclusion criteria

Exclusion criteria: Patients for whom catheter ablation for atrial fibrillation is contraindicated Patients with a history of thromboembolism or myocardial infarction within 2 months prior to enrollment

Design outcomes

Primary

Measure	Time frame
Composite of thromboembolic events and major bleedings within 1 month since catheter ablation procedure -Thromboembolic events; transient ischemic attack, ischemic stroke, non-CNS systemic embolism - Major bleeding; pericardial effusion requiring a drainage procedure (cardiac tamponade),puncture hematoma requiring surgery, other bleeding episodes requiring blood transfusion, intracranial hemorrhage	—

Measure

Time frame

Composite of thromboembolic events and major bleedings within 1 month since catheter ablation procedure -Thromboembolic events; transient ischemic attack, ischemic stroke, non-CNS systemic embolism - Major bleeding; pericardial effusion requiring a drainage procedure (cardiac tamponade),puncture hematoma requiring surgery, other bleeding episodes requiring blood transfusion, intracranial hemorrhage

—

Secondary

Measure	Time frame
- Thromboembolism within 1 month since catheter ablation procedure - Major bleeding within 1 month since catheter ablation procedure - Non-major bleeding within 1 month since catheter ablation procedure - Composite of thromboembolism and major bleeding within 1 month since catheter ablation procedure in a group of patients for whom the oral anticoagulation therapy was interrupted on the day of catheter ablation (interrupted regimen group) and in another group for whom the oral anticoagulation therapy was administered on the day of catheter ablation procedure (uninterrupted regimen group) - Non-major bleeding within 1 month since catheter ablation procedure in a group of patients for whom the oral anticoagulation therapy was interrupted on the day of catheter ablation (interrupted regimen group) and in another group for whom the oral anticoagulation therapy was administered on the day of catheter ablation (uninterrupted regimen group)	—

Measure

Time frame

- Thromboembolism within 1 month since catheter ablation procedure - Major bleeding within 1 month since catheter ablation procedure - Non-major bleeding within 1 month since catheter ablation procedure - Composite of thromboembolism and major bleeding within 1 month since catheter ablation procedure in a group of patients for whom the oral anticoagulation therapy was interrupted on the day of catheter ablation (interrupted regimen group) and in another group for whom the oral anticoagulation therapy was administered on the day of catheter ablation procedure (uninterrupted regimen group) - Non-major bleeding within 1 month since catheter ablation procedure in a group of patients for whom the oral anticoagulation therapy was interrupted on the day of catheter ablation (interrupted regimen group) and in another group for whom the oral anticoagulation therapy was administered on the day of catheter ablation (uninterrupted regimen group)

—

Countries

Japan

Contacts

Public ContactBell Medical Solutions, Inc.

Bell Medical Solutions, Inc. Clinical Research and Development Division

jimukyoku@medical-bs24.com0120-291-335

Outcome results